title: Primary cutaneous lymphoma: local control and survival in patients treated with radiotherapy.
abstract: BACKGROUND
  The treatment of primary cutaneous lymphoma is still ongoing and the role of radiotherapy, as exclusive or combined modality, is not yet clear.
  
  
  METHODS
  From 1994 to June 2004, 29 patients with cutaneous B-cell lymphoma and 9 patients with cutaneous T-cell lymphoma were treated by radiotherapy (median dose of 3900 cGy, range 600-4600 cGy). Eight patients had previously received chemotherapy.
  
  
  RESULTS
  The complete response rate was 94.7% with progressive disease in two patients (5%). Sixteen (42.1%) patients relapsed, with the relapse occurring only in the skin site as single episode (9 patients) and more than two episodes (7 patients). The 5-year overall survival and event-free survival were 94% and 53%, respectively.
  
  
  CONCLUSIONS
  Radiotherapy offers a substantial local control of primary cutaneous lymphoma, both as exclusive or combined approach. The patients with wide-spread or multiple lesions, usually candidates for radiotherapy and chemotherapy, are amenable to radiotherapy alone.
authors.affiliation: Radiotherapy Oncology, Department of Radiology, Università di Roma La Sapienza, Roma, Italy. vitaliana.desanctis@uniroma1.it
authors.forename: Vitaliana
authors.initials: V
authors.lastname: De Sanctis
authors.forename: Mattia F
authors.initials: MF
authors.lastname: Osti
authors.forename: Francesca
authors.initials: F
authors.lastname: Berardi
authors.forename: Francesca
authors.initials: F
authors.lastname: Ardito
authors.forename: Maurizio
authors.initials: M
authors.lastname: Valeriani
authors.forename: Maurizio
authors.initials: M
authors.lastname: Martelli
authors.forename: Riccardo Maurizi
authors.initials: RM
authors.lastname: Enrici
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000532:radiotherapy*; D016410:Lymphoma, T-Cell, Cutaneous / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D012878:Skin Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome